XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter
06 February 2009 - 6:40AM
PR Newswire (US)
VALLEY COTTAGE, N.Y., Feb. 5 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today provided
notification that on February 3, 2009 the Company received a letter
from a shareholder who owns more than 5% of the Company's
outstanding ordinary shares requesting the convening of an
extraordinary shareholders' meeting (EGM) of the Company as soon as
possible to address and approve the following matters: 1. that Boaz
Shweiger be and is hereby appointed as a Director of the Company
until the next annual general meeting of the Company; 2. that Mark
Allouche be and is hereby appointed as a Director of the Company
until the next annual general meeting of the Company; 3. that Amit
Yonay be and is hereby appointed as a Director of the Company until
the next annual general meeting of the Company; 4. that David
Grossman be and is hereby appointed as a Director of the Company
until the next annual general meeting of the Company; 5. that
Michael Weiss, Samuel Rudman and William Kennedy be removed from
their role as Directors of the Company; 6. that Yaron Diament be
and is hereby appointed as an External Director of the Company
until March 11, 2012; 7. that Dafna Cohen be and is hereby
appointed as an External Director of the Company until March 11,
2012; 8. that the share capital of the Company be consolidated and
re-divided so that each five (5) shares of NIS 0.02 nominal value
shall be consolidated into one (1) share of NIS 0.1 nominal value;
9. that the registered share capital of the Company be increased
from NIS 10,000,000 divided into 100,000,000 ordinary shares, NIS
0.1 nominal value, to NIS 70,000,000 divided into 700,000,000
ordinary shares, NIS 0.1 nominal value; 10. that the ADR ratio be
amended from one (1) ADR representing two (2) ordinary shares, NIS
0.1 nominal value, to one (1) ADR representing twenty (20) ordinary
shares, NIS 0.1 nominal value; 11. and that the remuneration terms
for Boaz Shweiger, Mark Allouche, Amit Yonay, David Grossman, Yaron
Diament and Dafna Cohen, as set forth in the Notice is hereby
approved. The EGMs will take place at the Conference Room at the
Company's Israeli offices at Building 3, Kiryat Weizmann Science
Park, Rehovot, Israel 76100, at 3:00 p.m. and 5:30 p.m. Israel time
on March 11, 2009. DATASOURCE: XTL Biopharmaceuticals Ltd. CONTACT:
Ron Bentsur, Chief Executive Officer of XTL Biopharmaceuticals
Ltd., +1-845-267-0707 ext. 224
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024